Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Barrett Esophagus 3Stomach Neoplasms 2Esophageal Neoplasms 2Colorectal Neoplasms 2Adenomatous Polyposis Coli 2Stomach Ulcer 1Lymphatic Metastasis 1Head and Neck Neoplasms 1Gastrointestinal Hemorrhage 1Gastrointestinal Diseases 1Gastritis 1Esophageal Squamous Cell Carcinoma 1Cholangiocarcinoma 1Carcinoma, Squamous Cell 1Carcinoma, Hepatocellular 1Adenocarcinoma Of Esophagus 1

Interventions

Gemcitabine 111Cisplatin 75Oxaliplatin 43pembrolizumab 34Fluorouracil 31Capecitabine 30durvalumab 26Leucovorin 25lenvatinib 23Magnetic Resonance Spectroscopy 14Irinotecan 13Nivolumab 12Albumin-Bound Paclitaxel 12Specimen Handling 11Radiofrequency Ablation 11Drug Therapy 11Biopsy 11tislelizumab 10pemigatinib 10apatinib 10Taxes 10Floxuridine 10130-nm albumin-bound paclitaxel 10Radiotherapy 9Bevacizumab 9Folfox protocol 8Carboplatin 8tremelimumab 7atezolizumab 7S 1 (combination) 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Cholangiocarcinoma × Gastroscopy × Clear all
NCT03942328 2026-04-20

Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer

Mayo Clinic

Phase 1/2 Recruiting
85 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡